Search

Author/Creator Al-Sawaf, Othman

3. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Issue 9 (September 2018)

Authors:
Cramer, Paula; von Tresckow, Julia; Bahlo, Jasmin; Robrecht, Sandra; Langerbeins, Petra; Al-Sawaf, Othman; Engelke, Anja; Fink, Anna-Maria; Fischer, Kirsten; Tausch, Eugen; Seiler, Till; Fischer von Weikersthal, Ludwig; Hebart, Holger; Kreuzer, Karl-Anton; Böttcher, Sebastian; Ritgen, Matthias; K...
Journal:
Lancet oncology
Issue:
Volume 19:Issue 9(2018)
Page Start:
1215
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Issue 10 (October 2017)

Authors:
Fink, Anna Maria; Bahlo, Jasmin; Robrecht, Sandra; Al-Sawaf, Othman; Aldaoud, Ali; Hebart, Holger; Jentsch-Ullrich, Kathleen; Dörfel, Steffen; Fischer, Kirsten; Wendtner, Clemens-Martin; Nösslinger, Thomas; Ghia, Paolo; Bosch, Francesc; Kater, Arnon P; Döhner, Hartmut; Kneba, Michael; Kreuzer, Ka...
Journal:
Lancet
Issue:
Volume 4:Issue 10(2017)
Page Start:
e475
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study. Issue 36 (20th December 2021)

Authors:
Al-Sawaf, Othman; Zhang, Can; Lu, Tong; Liao, Michael Z.; Panchal, Anesh; Robrecht, Sandra; Ching, Travers; Tandon, Maneesh; Fink, Anna-Maria; Tausch, Eugen; Schneider, Christof; Ritgen, Matthias; Böttcher, Sebastian; Kreuzer, Karl-Anton; Chyla, Brenda; Miles, Dale; Wendtner, Clemens-Martin; Eich...
Journal:
Journal of clinical oncology
Issue:
Volume 39:Issue 36(2021)
Page Start:
4049
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial. Issue 10 (October 2022)

Authors:
Cramer, Paula; Fürstenau, Moritz; Robrecht, Sandra; Giza, Adam; Zhang, Can; Fink, Anna-Maria; Fischer, Kirsten; Langerbeins, Petra; Al-Sawaf, Othman; Tausch, Eugen; Schneider, Christof; Schetelig, Johannes; Dreger, Peter; Böttcher, Sebastian; Kreuzer, Karl-Anton; Schilhabel, Anke; Ritgen, Matthia...
Journal:
Lancet
Issue:
Volume 9:Issue 10(2022)
Page Start:
e745
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Pooled analysis of first-line treatment with targeted agents in patients with chronic lymphocytic leukemia aged 80 years and older. Issue 14 (6th December 2022)

Authors:
Simon, Florian; Giza, Adam; Robrecht, Sandra; Fink, Anna-Maria; Cramer, Paula; von Tresckow, Julia; Fürstenau, Moritz; Goede, Valentin; Tausch, Eugen; Schneider, Christof; Stilgenbauer, Stephan; Wendtner, Clemens-Martin; Eichhorst, Barbara; Fischer, Kirsten; Hallek, Michael; Al-Sawaf, Othman
Journal:
Leukemia & lymphoma
Issue:
Volume 63:Issue 14(2022)
Page Start:
3299
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

8. Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Issue 5 (May 2021)

Authors:
Lescure, François-Xavier; Honda, Hitoshi; Fowler, Robert A; Lazar, Jennifer Sloane; Shi, Genming; Wung, Peter; Patel, Naimish; Hagino, Owen; Bazzalo, Ignacio J.; Casas, Marcelo M.; Nuñez, Sebastián A.; Pere, Yael; Ibarrola, Carlos M.; Solis Aramayo, Marco A.; Cuesta, Maria C.; Duarte, Andrea E.; ...
Journal:
Lancet
Issue:
Volume 9:Issue 5(2021)
Page Start:
522
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Issue 12 (15th October 2022)

Authors:
Wierda, William G.; Kipps, Thomas J.; Al-Sawaf, Othman; Chyla, Brenda; Biondo, Juliana M. L.; Mun, Yong; Jiang, Yanwen; Seymour, John F.
Journal:
Leukemia & lymphoma
Issue:
Volume 63:Issue 12(2022)
Page Start:
2765
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Issue 9 (September 2020)

Authors:
Al-Sawaf, Othman; Zhang, Can; Tandon, Maneesh; Sinha, Arijit; Fink, Anna-Maria; Robrecht, Sandra; Samoylova, Olga; Liberati, Anna M; Pinilla-Ibarz, Javier; Opat, Stephen; Sivcheva, Liliya; Le Dû, Katell; Fogliatto, Laura M; Niemann, Carsten U; Weinkove, Robert; Robinson, Sue; Kipps, Thomas J; Tau...
Journal:
Lancet oncology
Issue:
Volume 21:Issue 9(2020)
Page Start:
1188
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗